GrowthDifferentiation Factor 8 – Pipeline Review, H2 2019

“Global Markets Direct’s, ‘Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)- Pipeline Review, H2 2019’, provides in depth analysis on Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted pipeline therapeutics. The report provides comprehensive information complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics development and features dormant and discontinued projects. The report analyses the pipeline products from therapy areas Central Nervous System, Genetic Disorders, Musculoskeletal Disorders, Hematological Disorders and Oncology under development targeting Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN).

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

*Updated report will be delivered in 48 hours of order confirmation.”

Scope


– The report provides a snapshot of the global therapeutic landscape for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)

– The report reviews Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved in Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics and enlists all their major and minor projects

– The report assesses Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news and deals related to Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) targeted therapeutics”

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand the targeted therapy areas and indications for Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN)

- Identify the use of drugs for target identification and drug repurposing

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) development landscape

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Companies mentioned

“Acceleron Pharma Inc

Biogen Inc

Bioleaders Corp

Chugai Pharmaceutical Co Ltd

PeptiDream Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Scholar Rock Inc”

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Overview

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Companies Involved in Therapeutics Development

Acceleron Pharma Inc

Amgen Inc

Biogen Inc

Bioleaders Corp

F. Hoffmann-La Roche Ltd

PeptiDream Inc

Pfizer Inc

Regeneron Pharmaceuticals Inc

Scholar Rock Inc

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Drug Profiles

ACE-083 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ACE-2494 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ALG-802 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ATA-842 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BIIB-110 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLS-ILB-MD1 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

domagrozumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

luspatercept Drug Profile

Product Description

Mechanism Of Action

R&D Progress

REGN-2477 + trevogrumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SRK-105 Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit Myostatin for Duchenne Muscular Dystrophy Drug Profile

Product Description

Mechanism Of Action

R&D Progress

talditercept alfa Drug Profile

Product Description

Mechanism Of Action

R&D Progress

trevogrumab Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Dormant Products

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Discontinued Products

Growth/Differentiation Factor 8 (Myostatin or GDF8 or MSTN) Product Development Milestones

Featured News & Press Releases

Aug 31, 2018: Pfizer to abort trials of Duchenne muscular dystrophy drug

Jul 23, 2018: Acceleron Announces Preliminary Results from Part 1 of the ACE-083 Phase 2 Trial in Patients with Charcot-Marie-Tooth Disease at the 2018 Annual Meeting of the Peripheral Nerve Society

Jul 12, 2018: Acceleron Receives FDA Orphan Drug Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy

Jul 09, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and All Key Secondary Endpoints in Phase III ‘BELIEVE’ Study in Adults with Transfusion-Dependent Beta-Thalassemia

Jul 05, 2018: Acceleron Appoints Robert K. Zeldin, M.D., Chief Medical Officer

Jun 28, 2018: Celgene and Acceleron Announce Luspatercept Achieved Primary and Key Secondary Endpoints in Phase III 'MEDALIST' Study in Patients with Low-to-Intermediate Risk Myelodysplastic Syndromes

Jun 26, 2018: Acceleron to Present Preliminary Data on ACE-083 at the 2018 Annual Meeting of the Peripheral Nerve Society

Jun 15, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Beta-Thalassemia at the 23rd Congress of the European Hematology Association

Jun 04, 2018: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the ASCO 2018 Annual Meeting

May 31, 2018: Scholar Rock Announces Completion of Dosing of First Cohort in Phase 1 Clinical Trial of SRK-015

May 17, 2018: Acceleron Announces Presentations on Luspatercept at the 23rd Congress of the European Hematology Association

May 01, 2018: Acceleron Receives FDA Fast Track Designation for ACE-083 in Facioscapulohumeral Muscular Dystrophy

Apr 26, 2018: Acceleron Announces Presentations on Lead Product Candidate Luspatercept at the 2018 American Society of Clinical Oncology Annual Meeting

Apr 26, 2018: Acceleron Announces ACE-083 Phase 2 Trial Presentation at the American Academy of Neurology 70th Annual Meeting

Apr 15, 2018: Genentech to Present Phase Ib/II Study Results of RG6206

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

“List of Tables

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Indication, H2 2019

Number of Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019

Products under Development by Companies, H2 2019 (Contd..1), H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Stage and Route of Administration, H2 2019

Number of Products by Stage and Molecule Type, H2 2019

Pipeline by Acceleron Pharma Inc, H2 2019

Pipeline by Biogen Inc, H2 2019

Pipeline by Bioleaders Corp, H2 2019

Pipeline by Chugai Pharmaceutical Co Ltd, H2 2019

Pipeline by PeptiDream Inc, H2 2019

Pipeline by Pfizer Inc, H2 2019

Pipeline by Regeneron Pharmaceuticals Inc, H2 2019

Pipeline by Scholar Rock Inc, H2 2019

Dormant Products, H2 2019

Dormant Products, H2 2019 (Contd..1), H2 2019

Discontinued Products, H2 2019”

List of Figures

“List of Figures

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019”

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports